The evolution of antiplatelet therapy in cardiovascular disease (Q37900470)

25 August 2017

1 reference

title

The evolution of antiplatelet therapy in cardiovascular disease (English)

1 reference

25 August 2017

cardiovascular disease

1 reference

Omair Yousuf

1

1 reference

PubMed ID

21750497

25 August 2017

Deepak L Bhatt

series ordinal

2

1 reference

PubMed ID

21750497

25 August 2017

language of work or name

English

0 references

publication date

12 July 2011

1 reference

Nature Reviews Cardiology

25 August 2017

1 reference

25 August 2017

8

1 reference

25 August 2017

10

1 reference

25 August 2017

547-559

1 reference

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Intensifying platelet inhibition--navigating between Scylla and Charybdis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin resistance: more than just a laboratory curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Early versus delayed, provisional eptifibatide in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Ticlopidine versus aspirin after myocardial infarction (STAMI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial dama

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

The state of periprocedural antiplatelet therapy after recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Resisting the temptation to oversimplify antiplatelet resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Prasugrel in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Secondary prevention of stroke: can we do better than aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Antiplatelet therapies for the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

NSAIDS and the risk of myocardial infarction: do they help or harm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Glycoprotein IIb/IIIa inhibitors: do they still have a role?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Paraoxonase-1 is a major determinant of clopidogrel efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Triflusal for preventing serious vascular events in people at high risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.96

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).

31 March 2020

1 reference

12 December 2020

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention

1 reference

12 December 2020

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

1 reference

12 December 2020

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

1 reference

12 December 2020

Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials

1 reference

12 December 2020

The influence of low (81 mg) versus high (325 mg) doses of ASA on the incidence of sirolimus-eluting stent thrombosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2011.96

1 reference

25 August 2017

1 reference

PubMed ID

21750497